Last $0.37 USD
Change Today 0.00 / 0.00%
Volume 0.0
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated and ARE-SD Region No. 18, LLC Enter into Lease Agreement for Corporate Headquarters and Research and Development Laboratory

On December 31, 2014, OncoSec Medical Incorporated (the Company) and ARE-SD Region No. 18, LLC (the Landlord) entered into a Lease Agreement (the Lease Agreement). Pursuant to the Lease Agreement, the Company has leased certain premises of approximately 33,928 rentable square feet located at 5820 Nancy Ridge Drive, San Diego, California to serve as the company's corporate headquarters and research and development laboratory. The term of the lease agreement is expected to commence on or about October 1, 2015 (the Commencement Date), and expires one hundred twenty (120) months after the Commencement Date.

Oncosec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse

OncoSec Medical Inc. has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment. The study will enroll patients with treatment-refractory metastatic and unresectable SCCHN, regardless of HPV status. Eligible patients will receive up to nine cycles of IL-12 ImmunoPulse at six-week intervals and will be followed for clinical response and safety. The first stage of the study will enroll 20 patients with measurable disease. If three or more objective responses are observed, an additional 11 patients with measurable disease will be treated, for a total of 31 patients. The primary endpoint for this study will be best overall response by RECIST 1.1.

Oncosec Medical Inc. Announces Earnings Results for the First Quarter Ended October 31, 2014

OncoSec Medical Inc. announced earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.

OncoSec Medical Incorporated - Special Call

To consider recent milestone achievements and corporate and clinical development strategies, but will not address the company's results of operations or financial condition for a completed quarterly or annual fiscal period

OncoSec Medical Reports ImmunoPulse May Prolong Survival Based on Analysis of Long-Term Survival Data from Phase I Study in Melanoma

OncoSec Medical Incorporated released long-term survival results from its Phase I study in patients with metastatic melanoma, evaluating a single treatment cycle of intratumoral plasmid IL-12 (pIL-12) injection with electroporation (EP). OncoSec collected data from long-term follow-up and determined that the median overall survival for the patients in the Phase 1 study was 23.9 months. In addition, a statistically significant difference (p = 0.0054) was observed when comparing overall survival between patients who had a best overall response of at least stable disease or better (median OS = 49.1 months) versus patients who only had disease progression while on study (median OS = 10.9 months).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.37 USD -0.02

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.